Molecular pathogenesis of cervical cancer

Cancer Biology and Therapy

Volumn 11, Issue 3, 2011, Pages 295-306

  Ibeanu, Okechukwu A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Carcinogenesis; Cervix; Dysplasia; Early; Gene; HPV; Vaccine

Indexed keywords

PROTEIN E6; PROTEIN E7; VIRUS VACCINE;

CANCER MORTALITY; COLPOSCOPY; GENE FUNCTION; IMMUNOMODULATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIROLOGY; VIRUS GENE; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79951527044     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.3.14686     Document Type: Review

References (47)

1. Parkin D. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
2. McLaughlin-Drubin M, Munger K. Viruses associated with human cancer. Biochim Biophys Acta 2008;1782:127-50.
3. Chauhan S, Jaggi M, Bell M, Verma M, Kumar D. Epidemiology of human papillomavirus in cervical mucosa. Methods Mol Bio 2009; 471:439-56.
4. Einstein M, Schiller J, Viscidi R, Strickler H, Coursaget P, Tan T, et al. Clinicians guide to human papillomavirus immunology: knowns and unknowns. Lancet 2009;9:347-56.
5. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society 2008.
6. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virol 2009;384:260-5.
7. Lizano M, Berumen J, Garcia-Carranca A. HPV-related carcinogenesis: Basic concepts, viral types and variants. Arch Med Res 2009; 40:428-34.
8. De Villiers E, Fauquet C, Broker T, Bernard H, Zur Hausen H. Classification of papillomaviruses. Virol 2004; 324:17-27. (Pubitemid 38737395)
9. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev 2002; 2:342-50.
10. Schiffman M, Rodriguez A, Chen Z, Wacholder S, Herrero R, Hildesheim A, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence and cervical neoplasia. Cancer Res 2010; 70:3159-69.
11. Ho G, Bierman R, Beardsley L, Chang C, Burk R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8. (Pubitemid 28135669)
12. Lehoux M, D'Abramo C, Archambault J. Molecular mechanisms of human papillomavirus-induced carcinogenesis. Pub Health Genomics 2009; 12:268-80.
13. Wang S, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Nat Cancer Inst Monogr 2003; 31:35-40.
14. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006; 110:525-41. (Pubitemid 43736116)
15. Hebner C, Laimins L. Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006; 16:83-97.
16. Letian T, Tianyu Z. Cellular receptor binding and entry of human papillomavirus. Virol J 2010; 7:1-7.
17. Giroglou T, Florin L, Schafer F, Streeck R, Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 2001; 75:1565-70. (Pubitemid 32094716)
18. Hamid N, Brown C, Gaston K. The regulation of cell proliferation by the papillomavirus early proteins. Cell Mol Life Sci 2009; 66:1700-17.
19. Stubenrauch F, Laiminis L. Human papillomavirus life cycle: active and latent phases Sem Cancer Biol 1999;9:379-86.
20. Cullen A, Reid R, Campion M, Lörincz AT. Analysis of the physical state of different human papillomavirus RNAs in intraepithelial and invasive cervical neoplasia. J Virol 1991; 65:606-12.
21. Schwarz E, Freese U, Gissman L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314:111-4. (Pubitemid 15142033)
22. Howie H, Katzenellenbogen R, Galloway D. Papillomavirus E6 proteins. Virol 2009; 384:324-34.
23. Yugawa T, Kiyono T Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009; 19:97-113.
24. Wise-Draper T, Wells S. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci 2008;13:1003-17. (Pubitemid 351594744)
25. Yim E, Park J. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat 2005; 37:319-24.
26. Munger K, Baldwin A, Edwards K, Hayakawa H, Nguyen C, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78:11451-60. (Pubitemid 39390733)
27. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tomassino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Gene 2010; 40:1-13.
28. Scheffner M, Huibregtse J, Vierstra R, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505. (Pubitemid 23335075)
29. Martinez-Lagunas A, Madrid-Marina V, Gariglio P Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. Biochim Biophys Acta 2010; 1805:6-16.
30. Thomas M, Narayan N, Pim D, Tomaic V, Massimi P, Ngasaka K, et al. Human papillomaviruses, cervical cancer and cell polarity. Oncogene 2008; 27:7018-30.
31. McLaughlin-Drubin M, Munger K. The human papillomavirus E7 oncoprotein. Virol 2009; 384:335-44.
32. Liu X, Clements A, Zhao K, Marmorstein R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 2006; 281:578-86. (Pubitemid 43671221)
33. Ganguly N, Parihar S. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 2009; 34:113-23.
34. Mammas I, Sourvinos G, Giannoudis A, Spandidos D. Human papillomavirus (HPV) and host cellular interactions. Pathol Oncol Res 2008; 14:345-54.
35. zur Hausen H. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Nat Cancer Inst 2000; 92:690-8.
36. th Ed. Springer, New York 2002; 253-324.
37. Wright T, Kurman R. A critical review of the morphologic classification systems of preinvasive lesions of the cervix: the scientific basis of the paradigm. Papillomavirus Rep 1994; 5:175-81.
38. Fu Y, Braun L, Shah K, Lawrence WD, Robboy SJ. Histologic, nuclear DNA and human papillomavirus studies of cervical condylomas. Cancer 1983; 52:1705-11. (Pubitemid 13018294)
39. Holowaty P, Miller A, Rohan T, To T Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91:252-8. (Pubitemid 29090994)
40. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188:1383-92.
41. The ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188:1393-400.
42. Castle P, Schiffman M, Wheeler C, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia - grade 2. Obstet Gynecol 2009; 113:18-25.
43. Hildesheim A, Schiffman M, Gravitt P, Glass A, Greer C, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235-40. (Pubitemid 24045578)
44. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995; 171:1026-30.
45. Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 23:1-24.
46. Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D, et al. Efficacy of human papillomavirus A (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA); final analysis of a double-blind, randomized study on young women. Lancet 2009; 374:301-14.
47. Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.